Phio Pharmaceuticals Corp. — Form 8-K
Filed July 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Phio Pharmaceuticals appointed board-certified dermatologist Dr. R. Todd Plott to its Board of Directors on July 21, 2026. Dr. Plott brings 30+ years of dermatologic experience, prior FDA advisory committee service (2016–2021), and clinical trial oversight expertise. The appointment is intended to support advancement of PH-762, the company's lead siRNA candidate for squamous cell carcinoma and other skin cancers.
Why this rating
Board appointment adds relevant clinical/regulatory expertise but is routine governance. No material capital, revenue, or strategic change disclosed.
See more from July 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.